

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(S1) International Patent Classification 5 : C12N 7/00, 7/01, 15/00, 15/48, 15/85		A1	(11) International Publication Number: WO 94/29437 (43) International Publication Date: 22 December 1994 (22.12.94)
(21) International Application Number: PCT/US94/06415		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 7 June 1994 (07.06.94)		Published <i>With international search report.</i>	
(30) Priority Data: 08/073,345 7 June 1993 (07.06.93) US			
(71) Applicant: UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY [US/US]; 110 Administration Complex, 30 Bergen Street, University Heights, Newark, NJ 07101-3000 (US).			
(72) Inventor: DORNBURG, Ralph, C.; 15 Terry Avenue, South River, NJ 08882 (US).			
(74) Agent: MUCCINO, Richard, R.; P.O. Box 1267, Princeton, NJ 08542 (US).			

(54) Title: HIGHLY-EFFICIENT, SELF-INACTIVATING, RECOMBINATION-FREE, U3-FREE RETROVIRAL VECTORS

(57) Abstract

The present invention pertains to recombinant retrovirus vectors having a U3-free 5' LTR, a partially deleted 3' LTR, all essential cis-acting sequences for replication, an internal promoter recognizable by a selected host cell, and a non-retroviral gene under the control of the recognized promoter wherein (a) the U3-free 5' LTR is positioned 5' of the non-retroviral gene and has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer replacing the original U3 region of the 5'LTR; (b) the partially deleted 3' LTR is positioned 3' of the non-retroviral gene and has no U3 sequences except for those required at the attachment site for viral integration; (c) an exogenous polyadenylation addition signal sequence recognized by the selected host cell and positioned on the vector 3' to the 3'LTR viral integration site; and (d) the internal recognized promoter is positioned adjacent to the non-retroviral gene on the vector to permit expression of the non-retroviral gene in the host cell; whereby the vector can produce progeny virus in a helper cell with the progeny virus being capable of infecting the selected host cell and forming a provirus in the host cell, with the non-retroviral gene being expressible in the host cell, but the provirus in the host cell will be replication incompetent even in the presence of a helper virus.

AM

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Modaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mal	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

5

10

**HIGHLY-EFFICIENT, SELF-INACTIVATING,
RECOMBINATION-FREE, U3-FREE RETROVIRAL VECTORS**

15

BACKGROUND OF THE INVENTION

Field of the Invention

20

This invention relates to recombination-free, highly-efficient retroviral vectors that self-inactivate after one round of retroviral replication. The present vectors allow cell-type specific gene expression from tissue specific promoters and enhancers. The recombination-free retroviral vectors eliminate risks of downstream activation of cellular proto-oncogenes (tumorigenesis) that can occur with conventional vectors. This invention also relates to a retrovirus produced by the recombinant retrovirus vector and a host cell containing the provirus of the present invention.

25
30

Description of the Background

35

The disclosures referred to herein to illustrate the background of the invention and to provide additional detail with respect to its practice are incorporated herein by reference. For convenience, the disclosures are referenced in the following text and respectively grouped in the appended bibliography.

40

Retroviral vectors are the most efficient tools to introduce genes into vertebrate cells. Clinical experiments have been conducted to use retrovirus vectors

to cure a genetic disease in humans (adenosine deaminase (ADA) deficiency). Besides correcting inborn errors of metabolism, gene therapy is also being tested in clinical trials to cure cancer and various other diseases (Science 1992, Vol. 258, pp. 744-746).

5

Retroviral vectors are basically retroviral particles that contain a crippled viral genome in which all viral protein coding sequences have been replaced with the gene(s) of interest. As a result, such viruses cannot further replicate after one round of infection without the help of a helper virus. Retroviral 10 vector particles are produced by helper cells (Figure 1). Such helper cells contain plasmid constructs which express all retroviral proteins necessary for particle production and replication. After the introduction (transfection) of the retroviral vector genome into such helper cells, the vector genome (an RNA genome) is encapsidated into virus particles (due the presence of specific encapsidation 15 sequences). Virus particles are released from the helper cell carrying a genome containing only the gene(s) of interest (Figure 1). After infection of a fresh target cell, the RNA genome is reverse transcribed into DNA. The DNA copy is integrated into the host genome (Figure 2A). The integrated viral DNA is called the provirus. In the last decade, several retroviral vector systems, derived from 20 chicken or murine retroviruses, have been developed for the expression of various genes (for reviews see Temin, 1987; Gilboa, 1990).

25

Retroviral vectors have several limitations. For example, one major concern is the possible activation of proto-oncogenes as a result of the integration of the vector into the target cell genome. The activation of proto-oncogenes which is mediated by the viral LTR (Long Terminal Repeats) promoter and enhancer can lead to the malignant transformation (cancer) of the infected cell. Another problem with current retroviral vectors is regulated gene expression. Due to the presence of the retroviral LTR promoter and enhancer, it is impossible to design reliable vectors 30 for tissue specific gene expression.

35

To avoid these two shortcomings, retroviral vectors have been developed from murine leukemia virus (MLV) and spleen necrosis virus (SNV) that self-inactivate after one round of retroviral replication (Yu et al, 1986; Dougherty and Temin, 1987; United States patent no. 4,980,289 to Temin et al.). This has been achieved by deleting parts or almost all sequences of the retroviral U3 region of the right LTR (Figure 2B). As a result of the mechanism of the retroviral life-cycle, after one round of replication, a retroviral provirus is formed that does not contain LTR promoters.

However, in the case of MLV derived vectors, the efficiency of gene transduction was about four orders of magnitude less than that of a vector with two complete LTRs. In the case of SNV, efficiency of gene transduction decreased 5 only about tenfold. However, detailed investigations revealed that the U3-region of the right LTR was reconstituted in the helper cell (Olson et al., 1992). This reconstitution of the U3-region was the result of recombination (or gene conversion) of the vector with retroviral sequences present in the helper cell or in the other LTR.

10

To prevent such recombination events, new SNV-derived helper cells were constructed that express retroviral particle proteins from promoters and enhancers different from those present in the retroviral genome. Such new helper cells were termed DSN cells. DSN cells contain two separate plasmids for the expression of gag-pol and env proteins (Dougherty and Temin, 1989). One plasmid 15 contains the gag-pol gene of SNV which is expressed from the CMV promoter. The other plasmid contains the envelope gene unit of SNV which is expressed from the RSV promoter. Experiments performed with these new helper cells and SNV derived U3-minus vectors (e.g., pJD220SVHY, see Figure 3) revealed that the frequency of the recombination event(s) leading to a vector with two wild-type 20 LTRs was markedly reduced. However, vectors containing two wild-type LTRs were still recovered from transfected DSN helper cells (Dougherty et al., 1989). This finding showed that the (unaltered) U3-region of the left LTR of the vector construct can also serve as a template for the recombination (or gene conversion) 25 event resulting in the reconstitution of the U3-region of the right LTR.

BRIEF DESCRIPTION OF THE FIGURES

30

FIGURE 1 is a diagram illustrating retroviral helper cells producing recombination-free, self-inactivating retroviral vectors.

35

FIGURE 2 is a diagram illustrating retroviral vector replication.

FIGURE 3 is a diagram illustrating retroviral vectors derived from spleen necrosis virus (SNV).

- 4 -

FIGURE 4 is a diagram illustrating the nucleotide sequences at the junction of the cytomegalovirus (CMV) with spleen necrosis virus sequences as present in the pPO111 and pPO115 vector series.

5

SUMMARY OF THE INVENTION

The present invention pertains to a recombinant retrovirus vector
10 having a U3-free 5' LTR, a partially deleted 3' LTR, all essential cis-acting sequences for replication, an internal promoter recognizable by a selected host cell, and a non-retroviral gene under the control of the recognized promoter wherein:

(a) the U3-free 5' LTR is positioned 5' of the non-retroviral gene and has a transcriptional promoter and enhancer different from that of the original
15 retroviral promoter and enhancer replacing the original U3 region of the 5'LTR;

(b) the partially deleted 3' LTR is positioned 3' of the non-retroviral gene and has no U3 sequences except for those required at the attachment site for
viral integration;

(c) an exogenous polyadenylation addition signal sequence
20 recognized by the selected host cell and positioned on the vector 3' to the 3' LTR viral integration site; and

(d) the internal recognized promoter is positioned adjacent to the non-retroviral gene on the vector to permit expression of the non-retroviral gene in
the host cell;

25 whereby the vector can produce progeny virus in a helper cell with the progeny virus being capable of infecting the selected host cell and forming a provirus in the host cell, with the non-retroviral gene being expressible in the host cell, but the provirus in the host cell will be replication incompetent even in the presence of a helper virus.

30

The present invention also pertains to a retrovirus produced by the recombinant retrovirus vector and a host cell containing the provirus of the present invention.

35

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to recombination-free, highly-efficient retroviral vectors that self-inactivate after one round of retroviral replication. The vectors allow cell-type specific gene expression from tissue specific promoters and enhancers and eliminate risks of downstream activation of cellular proto-oncogenes (tumorigenesis) that can occur with conventional vectors. The present self-inactivating vectors eliminate the problems of recombination and give rise to high gene transfer efficiency, up to 1,000 fold higher than that of existing self-inactivating vectors. The vectors described herein are derived from spleen necrosis virus but vector modification may be made with any retroviral vector leading to similar results. Thus, the novel vectors have a high potential for use in human gene therapy and in other gene transfer applications in which the cell-type specific gene expression is required, e.g., tissue specific gene expression in transgenic animals.

To eliminate vector recombination and improve the efficiency of gene transduction, two modifications were made to a self-inactivating retroviral vector. First, the U3 region of the left LTR was replaced by the immediate early gene promoter and enhancer of the cytomegalovirus (CMV, Figures 3 and 4). This promoter was shown to be the strongest among a series of promoters tested for gene expression in a large variety of cell-types including the SNV promoter in D17 cells. In order not to abolish retroviral replication, the substitution of the U3 promoter by the CMV promoter was done in such a way that initiation of transcription started at the beginning of R as in the wild-type virus. In particular, if RNA transcription is initiated upstream of the original initiation site, first strand cDNA synthesis would result in a cDNA product abolishing replication. It may be transferred and hybridize to the R-region of the second RNA molecule. However, such a cDNA most probably could not function as a primer, since the immediate 3' nucleotides of that cDNA would not find homologous sequences for hybridization. Since the precise initiation of transcription was difficult to predict, three constructs (designated as pPO111-R1, pPO111-R2, and pPO111-R3) were made in which variable amounts of the U3 nucleotides upstream of the first nucleotide of R were retained (Figures 3 and 4). The function as well as frequencies of recombination of these constructs was tested as described earlier (Dornburg and Temin, 1988; Olson et al., 1992) and as described below. Second, the encapsidation region, as present in previous SNV derived vectors, was extended. Such additional sequences increase the efficiency of encapsidation of the vector genome into retroviral particles (Embreton and Temin, 1987).

In one embodiment of the present invention, the vector is a recombinant retrovirus vector having a normally replication incompetent retrovirus gene sequence with a foreign eukaryotic gene. The retrovirus gene sequence is prepared with a deficiency in the retrovirus promoter so that the vector can still produce progeny virus in a helper cell, with the progeny virus being capable of infecting a selected eukaryotic host cell, forming a provirus, and expressing the eukaryotic gene in the host cell, but the provirus will be defective in the retrovirus promoter sequence. Preferably, the vector is a recombinant plasmid. In another embodiment, a foreign internal promoter is positioned adjacent to the foreign eukaryotic gene on the vector to permit expression of the foreign eukaryotic gene in the eukaryotic host cell without initiating retroviral provirus gene expression. In one form, the reading direction of the foreign promoter is inverted relative to the normal reading direction of the retrovirus gene sequence, and a foreign 3' RNA processing sequence is positioned on the side of the foreign eukaryotic gene sequence which is opposite to the foreign promoter. In another embodiment, the retrovirus is a normally replication incompetent retrovirus of the type having a retrovirus portion and a foreign eukaryotic portion, the retrovirus portion having a deficient promoter portion, such that the virus is capable of infecting a eukaryotic host cell, forming a provirus, and expressing a eukaryotic protein coded for by the foreign eukaryotic portion in the host cell, but the provirus will be defective in a retrovirus promoter such that retroviral provirus gene expression doesn't take place in the host cell.

The present invention allows one to select a eukaryotic gene of interest, insert the gene into a vector designed in accordance with the present invention, transfect a helper cell with the vector, harvest virus stock from the helper cell, use the harvested progeny virus to infect a target cell, and have the proviruses which are formed in the target cells express the inserted eukaryotic gene without expressing any retroviral proteins. Since there is no retroviral promoter that is active on the provirus, endogenous helper proteins cannot trigger production of a virus from the provirus. Since there is no retroviral promoter in the provirus, the provirus cannot provide a retrovirus signal that might trigger the host cell to act in an unintended way. The lack of retroviral promoter stops production of retroviral RNA. This system renders much more likely the acceptability of recombinant retrovirus as drugs for vertebrates.

In the present invention, the enhancer and the promoter sequences of the retrovirus present at U3 in SNV have been deleted from the right side of the

DNA sequence in the plasmid vector (3'LTR). Only the sequences required at the attachment site for viral integration in the 3' LTR are present. The U3 5' LTR has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer to replace the original U3 region of the 5'LTR. The total lack of homology in the two U3 sequences prevent recombination. The U3 sequence normally present in the 5' LTR has been reported to be used as a template to repair a partially deleted U3 sequence in the 3' LTR. By eliminating the U3 sequence in the 5' LTR, the template for repair of the partially deleted U3 sequence in the 3' LTR is also eliminated. The vector DNA is used to transfect helper cells in a conventional manner. Because transcription from the vector begins at R on the left side, and because the promoter on the left side is not defective, virus can be harvested from the transfected helper cell in the conventional manner. Target cells can then be infected with the harvested virus. Since the right side U3 supplies the coding sequences for both U3 segments in the resulting provirus, the transcriptional promoter which was originally deleted on one side of the plasmid DNA shows up as being deleted from both sides in the resulting provirus. The vector therefore permits a stock of the retrovirus progeny virus to be grown up, yet will not permit further replication after one infection cycle.

If an internal promoter is not inserted, there will be no promoter to produce the desired foreign eukaryotic gene expression. Preferably such a promoter is positioned immediately adjacent to the foreign eukaryotic of interest so that no intervening retrovirus genes RNA is expressed. Because deletion of most of the U3 in SNV resulted in a loss of correct 3' end processing of viral RNA, even though AAUAAA was still present, a polyadenylation site was added to the vector. Moreover, problem recombinations are unlikely because the U3 sequences in the vector are not homologous.

Abbreviations used in the present invention are as follows: pro-promoter; enh-enhancer; PBS-primer binding site for DNA synthesis; PPT-polypurine track for DNA synthesis; E-encapsidation sequences for RNA packaging; attR+-a sequence that will form the right side of the attachment site relating to integration; attL+-the sequence that will form the left side of the attachment site relating to integration; attL+-the deletion of the original provirus left-side attachment site; and attR+-the deletion of the original right side attachment site.

The term "oligonucleotide" as used herein refers to primers, probes, oligomer fragments to be detected, oligomer controls, and unlabeled blocking

oligomers. Oligonucleotide are molecules comprised of two or more deoxyribonucleotides or ribonucleotides. The term "primer" as used herein refers to an oligonucleotide, preferably an oligodeoxyribonucleotide, either naturally occurring such as a purified restriction digest or synthetically produced, which is capable of acting as a point of initiation of synthesis when subjected to conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, *i.e.*, in the presence of nucleotides, an agent for polymerization such as a DNA polymerase, and a suitable temperature and pH. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the polymerization agent.

FIGURE 1 is a diagram illustrating retroviral helper cells producing recombination-free, self-inactivating retroviral vectors. FIGURE 1A shows cells (preferentially D17 cells=canine cells) transfected with two different plasmids expressing the retroviral gag-pol and env genes, respectively. These genes are expressed from promoters and enhancers different from the vector long terminal repeat LTR promoter and enhancer. FIGURE 1B shows that after the transfection of the retroviral vector genome into such helper cells, viral particles are produced that contain the RNA vector genome with the gene of interest.

FIGURE 2 is a diagram illustrating retroviral vector replication. FIGURE 2A shows an example of a conventional retroviral vector provirus as present in the helper cell shown at the top. This vector contains wild-type long terminal repeats with full-length U3, R, and U5 regions. RNA transcription yields the RNA transcript shown below. This RNA contains an encapsidation sequence (E) and all other cis-acting sequences necessary for replication (pbs = primer binding site, ppt = polypurine tract). After infection of a fresh target cell the retroviral genome is reverse transcribed into a double-stranded DNA copy. During this process, the U3-region which contains the retroviral promoter and enhancer and which is present at the 3' end of the RNA genome is duplicated and attached to the 5' end of the DNA copy. In a similar way, the U5 region, present only at the 5' end of the RNA genome, is also duplicated and attached to the 3' end of the DNA copy. The double-stranded DNA copy is integrated into the genome of the infected cell. Due to the presence of two long terminal repeats which contain the retroviral enhancer and promoter, tissue specific gene expression cannot be obtained. Further, the downstream enhancer and promoter can activate gene expression of genes located downstream of the integrated provirus (indicated by an arrow). FIGURE 2B illustrates the principle of a self-inactivating retroviral vector. The vector present in the helper cell is shown at the top. This vector is almost identical

to the one shown above. However, the long terminal repeat at the right side has been modified in the following way: most of U3-sequences including the promoter and enhancer sequences have been deleted. Maintenance of some U3-sequences that form the attachment site (att) is essential for the efficient integration of the vector genome. The RNA transcribed from the U3-minus vector virus does not contain the retroviral promoter and enhancer. Thus, after one round of retroviral replication, a promoter-less retroviral provirus is formed. Genes can be expressed from internal tissue-specific promoters (pro).

FIGURE 3 is a diagram illustrating retroviral vectors derived from spleen necrosis virus (SNV). The SNV genome (provirus) is shown at the top. An example of a standard retroviral derived from SNV is shown below (pJD214HY). In all SNV-derived standard vectors, the protein coding regions (gag-pol and env, the region from Sal1 to the 3' end of env) have been replaced with the gene(s) of interest (in pJD214HY with hygromycin resistance gene, referred to as hygro). pJD220SVHY is a first generation self-inactivating retroviral vector in which the retroviral promoter and enhancer of the right LTR have been deleted (designated as U3 minus; for more details, see Figure 2B). To increase efficiency of replication, the polyadenylation sequence of simian virus 40 (SV40ter) has been inserted downstream of the U3-minus LTR. To avoid problems of recombination of first generation U3-minus vectors in the pPO111 vectors, the U3 region of the left LTR has been almost completely deleted (except a few nucleotides to guarantee correct initiation of transcription) and substituted for the immediate early promoter and enhancer of the human cytomegalovirus (CMV, for more details, see also Figure 4). Further, this second generation, U3-free vector contains additional retroviral sequences (from Sal1 to Eag1) to increase the efficiency of encapsidation. A universal, second generation U3-free vector (pPO115-R1) contains a multiple cloning site replacing the promoter (SV40pro) and hygromycin B resistance gene (hygro) as present in pJD220SVHY and pPO111-R1 (from Eag1 to Cla1). The multiple cloning site has been derived from pBluescript II (Eag1 to Cla1) and allows the easy insertion of various genes and promoters to give new retroviral vectors.

FIGURE 4 is a diagram illustrating the nucleotide sequences at the junction of the cytomegalovirus (CMV) with spleen necrosis virus sequences as present in the pPO111 and pPO115 vector series. An except of the SNV genome showing the TATA box and initiation of transcription is shown at the top. The Sac1 site downstream of the TATA box of the CMV immediate early promoter (shaded sequence) was used for cloning to connect the CMV promoter and enhancer

to the SNV sequences. pPO111-R2 and pPO111-R3 are 3 or 9 nucleotides shorter than pPO111-R1, respectively.

The function of the new vectors was tested in a tissue culture system
5 as follows and as described earlier (Olson et al., 1992): The new vector constructs
pPO111-R1, pPO111-R2, and pPO111-R3 were transfected into helper cells. In
parallel, the retroviral vectors pJD214HY, a standard retroviral vector with two
complete wild-type LTRs, and pJD220SVHY, the first generation self-inactivating
vector from which the new vectors have been derived (Figure 3), were also
10 transfected into helper cell-lines. Transfected cells were selected for hygromycin
resistance and cell-lines were established. These resulting helper cell lines are
designated as step 1 cells. Virus was harvested from confluent step 1 cultures and
fresh helper cells were infected. The infected helper cells were termed step 2 cells.
Virus titers were determined (Table 1). We show that the new vectors pPO111-R1
15 to pPO111-R3 were more efficient than pJD220SVHY. They were almost as
efficient as a vector with two wild-type LTRs (pJD214HY).

To test for recombination, virus particles were harvested from
confluent step 2 cell cultures (mass infection) and fresh D17 cells were infected.
20 Detection of hygromycin resistant colonies indicates that recombination
reconstituted the U3 region: due to the lack of control sequences in RNA
transcripts derived from completely U3-minus proviruses, such vectors are not
further passaged by retroviral proteins. Thus, only vectors with complete, repaired
LTRs are transferred to new target cells. We found that pJD220SVHY was further
25 passaged with high efficiency confirming earlier findings (Olson et al., 1992). The
new vectors pPO111-R1 to R3, however, were not further transferred from step 2
helper cells (Table 1). These data show that the new vectors are resistant to
recombination events that reconstitute the LTR region.

TABLE 1

EFFICIENCY OF INFECTIVITY AND RECOMBINATION OF SELF-INACTIVATING RETROVIRAL VECTORS DERIVED FROM SNV

5

VECTOR NAME	VIRUS TITER (CFU)	
	1. INFECTION	2. INFECTION
pJD214HY	6 x 105	5 x 106
pJD220SVHY	8 x 104	1 x 103
pPO111-R1	4 x 105	0*
pPO111-R2	2.5 x 105	0*
pPO111-R1	1.5 x 105	0*

* No hygromycin resistant colonies were obtained with pPO111 vectors.

15

The retroviral vectors (see also Figure 3) were transfected into helper cells followed by hygromycin selection. Virus was harvested from confluent cultures and fresh helper cells were infected (referred to as first infection). Infected cells were selected for hygromycin resistance, and virus titers were determined (expressed as colony forming units (CFU) per ml of supernatant medium). Cell-lines were established from infected tissue culture plates which contained more than 1,000 independent hygromycin resistant colonies. Virus was harvested from confluent cell cultures and fresh D17 cells were infected (referred to as second infection). Infected cells were selected for hygromycin resistance and virus titers were determined.

20

25

Examples

Materials and Methods

30

Plasmid construction.

The immediate early promoter and enhancer of cytomegalovirus, CMV (a 900 bp Hind3 fragment obtained from plasmid pJDCMV19SV, Dougherty et al., 1990) was cloned into plasmid pRD15 (described in Sheay et al., submitted

35

for publication). The resulting plasmid was termed pPO101. A DNA fragment containing most of the LTR, the encapsidation region, and parts of the gag-pol region of spleen necrosis virus (a Ball fragment derived from plasmid pSW253, described by Watanabe and Temin, 1982) was cloned into the blunted Sac1 site of pBluescript II KS. The resulting plasmid was termed pPO102. Plasmid pPO102 was digested with Sac1 and re-ligated after treatment with Klenow polymerase 1 (creation of blunt ends) to eliminate a Sac1 site present in the encapsidation sequence. The resulting plasmid was termed (pPO102-S). Using PCR technology and plasmid pPO102-S as template, three DNA fragments were generated comprising slightly different amounts of the SNV R, U5, and encapsidation region: a DNA fragment termed R1 comprises map units 383 to 986 of the SNV genome, fragment R2 comprises map units 385 to 986, and fragment R3 comprises map units 392 to 986. All PCR primers contained Sac1 recognition sites at their 5' ends. After Sac1 digestion, fragments R1, R2, and R3 were cloned into the Sac1 site of pBluescript II KS. The resulting plasmids were termed pPO103-R1, pPO103-R2 and pPO103-R3, respectively. Fragments R1 to R3 were isolated from such plasmids and cloned into the Sac1 site of pPO101. The resulting plasmids were termed pPO104-R1, pPO104-R2, and pPO104-R3, respectively.

Plasmid pJD220SVHY (Dougherty and Temin, 19986) was digested with Ssp1 and Sac1. After Klenow pol1 treatment, a linker coding for the recognition site of the restriction enzyme Bgl2 was ligated. This procedure removed the left LTR promoter, and all of the encapsidation sequences present in this vector. The resulting plasmid was termed pPO106. DNA fragments derived from plasmids pPO104-R1, pPO104-R2, and pPO104-R3 comprising the CMV promoter, R, U5, and the encapsidation sequence (Bgl2 fragments) were isolated and inserted into plasmid pPO106 digested with Bgl2. The resulting plasmids were termed pPO111-R1, pPO111-R2, and pPO111-R3, respectively. The universal retrovirus vectors pPO115-R1 and PPO115-R2 were made by replacing the SV40 promoter and hygromycin B phosphotransferase gene of pPO111-R1 and pPO111-R2 (Eag1 to Cla1 fragment) with the multiple cloning site (Eag1 to Cla1) of pBluescript II KS.

DNA sequence pPO111-R1 5528 b.p. complete sequence;

CAGATCTGAGCTTGCATTGCATACGTTATCCATACTAAATATGTACATTATGGCTA
 5 TGTCACACATTACCGCCATGTCACATTGATTATGACTAGTTATAATAGTAATCAATTACGGG
 GTCATTAGTCATGCCATATGGAGTCCCGTACATAACTACGGTAAATGGCCGCCCTG
 GCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTCCTAGTAACGCCA
 ATAGGGACTTCCATTGACGTCAATGGGTGGAGTATTCACGGTAAACTGCCACTTGGCAGTACA
 TCAAGTGTATCATATGCCAAGTGACCCCCATTGACGTCAATGACGGTAAATGGCCGCCCTGGC
 ATTATGCCAGTACATGACCTATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATC
 10 GCTATTACCATGGTGTGCGGTTTGGCAGTACATCAATGGCGTGGATAGCGGTTTACTCACG
 GGGATTCCAAGTCTCCACCCATTGACGTCAATGGAGTTTGGCACC AAAATCAACGGG
 ACTTCCAAAATGTCGAACAACCTCCGCCATTGACGCAAATGGCGGTAGCGTACGGTGG
 GAGGTCTATATAAGCAGAGCTCATCTTGTCTCGGGGTGCGCGTCTGCACATTGTTGTGAC
 GTGCCGCCAGATTCGAATCTGTATAAAACTTTTTCTGAATCCTCAGATTGGCAGTGA
 15 AGGAGATTTTCTCGTGGTGTGCTGGCTACTGGGTGGCGCAGGGATCGGACTGAATCCGT
 AGTACTCGGTACAACATTGGGGCTCGTCCGGGATACCCCTCCCATCGGAGGGTGCCAACT
 GCTTCYTCGAACTTCTCGAACCTCCGGCGCGGTGAGTTAAAGTACTTGATTTGGTACCTCGG
 AGGGTTTGGAGGATCGGAGTGGTGGCGGAGCTGCCACCTCCGCTCAGCAGGG
 GACGCCCTGACCTGAGCTGAATTCAGATCTTGTGGTATCTGATTGTTGAGCCGTCCTAAG
 20 ACGGTGATACTAAGTCGTGGTGTGTTGTTGCTTGTGTTGTCGTGTTGTCGA
 CAGCGCCTTGCATTGGTGTACCCACCCGCGGGCTTGCATAAAATACTTTGGAGAGCCTTT
 GCCTCCAGTGTCTCCGTGTACTCGTCCCTCCCTCCGCGGGAGAGCTGCCCGGG
 GATCCTCTAGTATGGTCACTCTCAGTACAATCTGCTGTGCGCATAGTTAAAGCAGTATAC
 ACTCCGCTATCGTACCTGACTGGGTATGGCTGCGCCCGACACCGCAAACACCGCTGACGC
 25 GCCCTGACGGGCTTGTGTCGTCCCGGATCCGCTTACAGACAAGCTGTGACCGTCTCCGGAGCT
 GCATGTGTCAGAGGTTTCAACCGTCAACCGGAAACCGCGAGGGCAGCTGTGGAATGTGTCAG
 TTAGGGTGTGAAAGTCCCAGGGCTCCCGAGCAGGGCAGAAGTATGCAAAGCATGCACTCAATT
 GTCAAGCAACCAGGCTCCCGAGCAGGGCAGAAGTATGCAAAGCATGCACTCAATTAGTCAGCAACC
 ATAGTCCCGCCCTAACTCCGCCATCCGCCCTAACTCCGCCAGTTCCGCCATTCTCCGCC
 30 CCATGGCTGACTAATTTTTATTATGCAGAGGGCGAGGCCCTCGGCCCTTGAGCTATCC
 AGAAGTGTGAGGGAGCTTTGGAGGCCCTAGGCTTTGCAAAAGCTTAGAGTGCACCTGCA
 GCCCAAGCTGATCCCGGGGGCAATGAGATATGAAAAGCCTGAACTCACCGGACGTGTCGA
 GAAGTTCTGATCGAAAAGTTCGACAGCGTCTCCGACCTGTGCAAGCTCTGGAGGGCGAAGAAT
 CTGGTCTTCAGETTCGATGTAAGAGGGCTGGATACTCTCGGGTAAATAGCTGCCCGAT
 35 GGTTTCTACAAAGATCGTATGTTATCGGCACTTGCACTGGCCGCGCTCCGATTCCGGAAGT
 GCTTGACATTGGGAAATTAGCGGAGAGCTGACCTATTGCACTCTCCGCGTGCACAGGGTGTCA
 CGTTGCAAGACCTGCTGAAACCGGAACTGCCGCTGTTGCAAGCCGTCGCGGAGGCCATGGAT
 GCGATCGCTGCCGGATCTTAGGAGACGAGCCGGTCCGCCATTCCGACCGAAGGAATCGG
 TCAATACACTACATGGCGTATGTTCATATGCGCATTGCTGATCCCCATGTGATCACTGGCAA
 40 CTGTGATGGACGACACCGTCAGTGGCTCGTGCACCGGCTCAGTGGCTGAGCTGATGCTTGGGCC
 GAGGACTGCCGAAAGTCCGGCACCTCGTGCACCGGATTTCGGCTCAACAATGCTCTGACGGA
 CAATGGCCGATAACAGCGTCACTGACTGGAGGGCGATGTCGGGATTCCAATACGAGG
 TCGCCAACATCTCTCGAGGGCGTGGTGGCTTGATGGACAGCAGACGCGCTACTTCGAG
 CGGAGGCGATCCGGAGCTTGCAGGATGCCGCGGCTCCGGCGTATATGCTCCGATTGGTCTGCA
 45 CCAACTCATCAGAGCTGGTTGACGGCAATTGATGATGCACTTGGCGCAGGGTGTGATGCG
 ACGAATCGTCCGATCCGGAGCGGGACTGTCGGCGTACACAAATGCCGAGAAGCGGGCC
 GTCTGGACCGATGGCTGTTAGAAGTACTCGCGATGTTGAAACCGACGCCAGCACTCGTGG
 GATCAGCTGGCACTGGATTAAATTCTCATGTTGACAGCTTATCATGATAAGCTTAGGTCAA
 TGGTTGACCAAGACATACAAGAGCAGTGGGAATGTGGAGGGCTCGAGGTGGGGTGGCGT
 50 CCTACACATTGTTGACGGCTGGGCCAGATTCGAATCTGATAAAACCTTTTAACG
 AATCCCTCAGATTGGCAGTGAGAGGAGATTGTTGCTGGTGTGGCTGGCCTACTGGTGGCGC
 AGGGATCGATCCAGACATGATAAGATACTTGATGAGTTGGACAAACACAACAGTAAATGCA
 GAAAAAAATGCTTATTGTGAAATTGATGCTATTGCTTATTGTAACCAATTAAAGCTG
 AATAAACAGTTAACAAACAATTCGATTCTTATGTTGAGGTCAAGGGGAGGTGTGGGA
 55 GGTTTTAAAGCAAGTAAACACAAATTCGATTCTACAAATCAAGCTGATCCCTGCTCGCGTTCGGTGT
 GACGGTAAACCTCTGACACATGCACTGGCTCCGGAGCGGTACAGCTGTCGTAAGCGGATGC
 CGGGAGGAGACAAGCCGTCAGGGCGTCAAGGGGTGTTGGCGGGTGTGGGGCGAGCCATGA
 CCCAGTCACGTAGCGATAGCGGAGTGTACTGGCTTAACATGCGCATCAGAGCAGATTGAC

- 14 -

5 TGAGAGTGACCATATCGGGTGTAAATACGCCACAGATGCGTAAGGAGAAAATACCGCATTAGG
 CCCTTCCGCTCCCTCGCTACTGACTCGCTCGTCGGCTGGCTGCGGAGCGGTATC
 AGCTCACTCAAAGGCCGTAATACGGTTATCCACAGAATCAGGGATAACCCAGGAAGAACATGT
 GAGCAAAAGGCCAGCAAAGGCCAGGAACCGTAAAGGCCCGCTGGCTGGCTTCCATAGG
 10 5 CTCGCCCTGACGAGCATCACAAATCGACGCTCAAGTCAGAGGTGGCAGAACCCGACAGG
 ACTATAAAAGATAACCAGCGTTCCCGTGGAAAGCTCCCTCGTCGCTCTCTGTTCCGACCCCTGC
 CGCTTACCGGATAACCTGTCGGCTTCCCGTGGAAAGCGTGGCGCTTCTCATAGCTCACGC
 TGTAGGTATCTCAGTCGGTGTAGGTGCTCCAGCTGGGCTGTGTGACGAACCCCCGT
 TCAGCCCACCGCTGCGCCTATCCGGTAACTATCGTCTTGAGTCAACCCGTAAGACACGACT
 15 10 TATGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGGCGTCTACA
 GAGTTCTTGAAGTGGTGGCTAACTACGGCTAACAGTAGAAGGACAGTATTTGGTATCTGCGCTCT
 GCTGAAGCCAGTTACCTCGGGAAAAGAGTTGGTAGCTTGTATCCGCAACAAACCCACCGCTG
 GTAGCGGTGGTTTTTGTGCAAGCAGCAGATTACGCGAGAAAAAGGATCTAAGAAGAT
 CCTTGATCTTCTACGGGCTGACGCTCAGTGGAACGAAAATCACGTTAAGGGATTTGGT
 20 15 CATGAGATTATCAAAGGATCTCACCTAGATCCTTTAAATTAAAATGAAGTTAAATCAA
 TCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATC
 TCAGCGATCTGCTATTCGTTCATCCATAGTGCGTACTCCCCGTCGTAGATAACTACGAT
 ACGGGAGGGCTTACCATCTGGCCCCAGTGTGCAATGATAACCGCAGAACCCACGCTCACGGCTC
 CAGATTTATCAGCAATAACCGCCACCGGAAGGGCGAGCGCAGAAGTGGTCTGCAACTTA
 25 20 TCCGCTCCATCCAGTCATTAATTGTTGCGGGAAAGCTAGAGTAAGTAGTTGCGCAGTTAATAG
 TTTGCGCAACGTTGTTGCCATTGCTGAGGATCAGTGTGTCACTGCTCGTGTGGTATGGCTT
 CATTCACTCCGGTCCCAACCATCAAGCGAGTTACATGATCCCCATGTTGTGCAAAAAGCG
 GTTAGCTCCTCGGTCTCCGATCGTTGTCAAGAAGTAGTTGGCCGAGTGTATCACTCATGGT
 TATGGCAGCACTGATAATTCTTACTGTGATGCCATCCGTAAGATGCTTTCTGACTGGT
 30 25 AGACTCAACCAAGTCATTCTGAGAATAGTGTATGCGCGACCGAGTTGCTCTTGCCCCGGTCA
 ACACGGGATAATACCGCCACATAGCAGAACCTTAAAGTGTCTCATCATTGGAAAACGTTCTC
 GGGCGAAAATCTCAAGGATTTACCGCTGTGAGATCCAGTTGATGTAACCCACTCGTCAC
 CCAACTGATCTCAGCATCTTTACTTTCACCGGTTCTGGTGAGCAAAACAGGAAGGCAA
 AATGCCGAAAAAAGGAAATAAGGGCACACGGAAATGTTGAATACTCATCTTCTTTCA
 30 ATC

DNA sequence pPO111-R2 5525 b.p. complete sequence;

35 35 CAGATCTGAGCTGCCATTGCAATACGGTTATCCATATCATAATATGACATTATATTGGCTCA
 TGTCACCATACGCCATGTTGACATTGATTATTGACTAGTTAAATGTAATCAATTACGGG
 GTCATTAGTTCATAGCCCATATATGGAGTCCGCTTACATAACTACGGTAATGGCCGCTG
 GCTGACCGCCAAACGACCCCCCCCCATTGACGTCATAATGACGTATGTCATAGTAACGCCA
 ATAGGGACTTCCATTGACGTCATGGTGGAGTATTACGGTAACCTGCCACTGGCAGTACA
 40 40 TCAAGTGTATCATATGCCAAGTACGCCCTATTGACGTCATGACGGTAATGGCCGCTGGC
 ATTATGCCAGTACATGACCTTATGGACTTTCTACTTGGCAGTACATCTACGTTAGTCATC
 GCTATTACCATGGTATGGCTGGGAGTGGACTTGGCAGTGGGATAGCGGTTGACTCAG
 GGGATTTCAGTCTCACCCATTGACGTCATGGAGTTGGGACCAAAATCAACGGG
 ACTTTCCAAAATGTCGTAACAACACTGCCCTATTGACGCAATGGCGGTAGGGTGTACGGTGG
 45 45 GAGGTCTATATAAGCAGAGCTCTGGCTGGGGTGCCTGCACATTGTTGTGACGTG
 CGGCCAGATTCGAATCTGTAATAAAACTTTTTCTGAATCCTCAGATTGGCAGTGAGAGG
 AGATTTGTTGCTGGTGTGCTGCCACTGGGTGGCGCAGGGATCCGGACTGAATCCGTAGT
 ACTTCGGTACAACATTTGGGGCTGTCGGGATAACCCCTCCCATGGCAGAGGTGCCAATGCT
 TCTCGAACTTCTCGAACTCCGGCGCCGTGAGTTAAGTACTTGTATTTGGTACCTCGCGAGG
 50 50 GTTGGGAGGATCGGAGTGGTGGCGGGACCGCTGCCGGAAAGCTCCACCTCCGCTCAGCAGGGAC
 GCCCTGACCTGAGCTCGAATTCAAGTCTTGTGGTATCTGATTGTTGTTGAGCCGTCCTAAAGACG
 GTGATACTAAGTCGTGGCTTGTGTTGTTGTTGCTTGTGTTGTCGCTGGTGTGACAG
 CGCCTTGCAGATTGGTGTACCCACCCGCGCCGTGCGAATAATACTTGGAGAGGCCCTTGGC
 TCCAGTGTCTCCGCTGTACTCGTCCTCTCCCTCTCCGGCGGGAGAGCTGCCGGGGAT
 55 55 CCTCTAGTATGGTGCAGTCAGTACAATCTGCTCTGATGCCGATAGTTAGCCAGTACACT
 CGCCTATCGCTACGTGACTGGGTATGGCTGCCCGACACCCGCCAACACCCGCTGACCGC
 CTGACGGGCTGTCTGCTCCCGCATCCGTTACAGACAAGCTGTGACCGTCTCGGGAGCTGCA
 TGTCAGAGGTTTACCGTCATCACCAGAAACGCGCGAGGCAGCTGTTGAATGTTGTCAGTTA

GGGTGTGAAAGTCCCCAGGCTCCCAGCAGGAGAAGTATGCAAAGCATGCATCTCAATTAGTC
 AGCAACCAGGCTCCCAGCAGGAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATA
 GTCCCGCCCTAACTCCGCCATCCGCCCTAACCTCCGCCAGTTCCGCCATTCTCCGCCCA
 TGGCTGACTAATTTTTTATTTTGAGGCCCTAGGCTTTGCAAAAAGCTCTAGAGTCACCTGCAGCC
 5 AGTAGTGAAGGAGGTTTTGGAGGCCCTAGGCTTTGCAAAAAGCTCTAGAGTCACCTGCAGCC
 CAAGCTGATCCCCGGGGCAATGAGATATGAAAAAGCCTGAACTCACCGGACCTCTGTCAGAA
 GTTTCTGATCGAAAAGTTCGACACGCTCCGACCTGATGCACTCTCGAGGGCGAAGAATCTC
 GTGCTTCAGCTTCGATGTAGGAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCATGGT
 TTCTACAAAAGATCGTTATGTTATCGGCACTTGCATCGCCGCCGCTCCGATTCGGAAGTGCT
 10 TGACATTGGGAATTCAAGCAGAGCCTGACCTATTGCACTCCCGCTGCACAGGGTGTACGGT
 TGCAAGACCTGCGTAAACCGAAGTGCCTGCTGAGCCGCTCGGAGGGCATGGATGCG
 ATCGCTGCCCGATCTTAGCCAGACGAGCGGGCTCGGCCATTGAGCCGCAAGGAATCGGTCA
 ATACACTACATGGCGTATTTCATATGCGCGATTGCTGATCCCCATGTTATCACTGGCAAACCTG
 TGATGGACGACACCGTCACTGCGTCCGTCGCGCAGGCTCTGATGAGCTGATGCTTGGCCGAG
 15 GACTGCCCCGAAGTCCGGCACCTCGTCACCGGATTTGGCTCCAACAATGTCCTGACGGACAA
 TGGCCGATAACACCGGTATTGACTGGAGCAGGCGATGTTGGGGATTCCCAAACAGAGGTGCG
 CCAAACATCTCTTGAGGCCGTTGGCTTGCTGATGGAGCAGACGCGCTACTTCGAGCGG
 AGGCATCCGGAGCTTGCAGGATGCCGCCGCTCCGGCGTATATGTCGCCATTGGTCTGACCA
 ACTCTATCAGAGCTGGTTGACGGCAATTGATGATGCACTGGCGCAGGGTGTGACGACG
 20 CAATCGTCCGATCCGAGCCGGACTGTCGGCGTACACAAATGCCCGCAGAACGCGGCCGTC
 TGGACCGATGGCTGTAGAACTCGCGATAGTGGAAACCGACGCCGACTCGTGGGAT
 CAGCTGGCACTGGAATTAAATTCTCATGTTGACAGCTTATCATGATAAGCTTAGGTCAATGG
 TTTGACAGAAACATACAAGAGCAGTGGGAATGTTGGAGGCCCTGAGGTGGGGTGGCGTCC
 ACACATTGTTGTTGACCGTGGCCAGATTGCAATCTGTAATAAAACCTTTTAACGAA
 25 CCTCAGATTGGCACTGAGGAGATTGTTGTTGTTGTTGCTGGCTACTGGGTGGCGCAGG
 GATCGATCCAGACATGATAAGATACTTGTAGGTTGACAAACACAACTAGAATGCACTGAA
 AAAAATGCTTATTGAAATTGATGCTATTGCTTTATTGTAACCTATAAGCTGCAAT
 AAACAAGTTAACACAACAACTGCAATTGCAATTGTTAGGTTCAAGGGGAGGGTGTGGAGG
 TTTTAAAGCAAGTAAACCTCTACAAATCAAGCTGATCCCTGCCCTGCCGTTGGTGTGAC
 30 GGTGAAAACCTGACACATGCACTGGAGACGGTACAGCTTGTGTAAGGGGATGCCG
 GAGCAGACAAGCCGTAGGGCGCGTCAGGGGTGTTGGGGGTGCGGGCGAGCCATGACCC
 AGTCACGTAGCGATAGCGGAGTGTACTGGCTTAACTATGCGCATCAGCAGATTGACTGA
 GAGTCACCATATGGCGTGTAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGCGC
 TCTCCGCTTCTCGTCACTGACTCGCTGCCCTGGCTTGGCTTGGCGAGGGTATCAGC
 35 TCACTCAAAGCGGTAAACGGTTATCCACAGAATCAGGGATAACGCAAGGAAAGACATGTGAG
 CAAAGGCCAGAAAAGGCCAGGAACCGTAAAAGGCCGCTGGCTGGCTTTCCATAGGCTC
 CGCCCCCTGAGCGATCACAAAATGACGCTCAAGTCAGGGTGGCGAAACCCGACAGGACT
 ATAAGATAACAGGGCTTCCCCCTGGAAGCTCCCTCGTGGCTTCCCTGTTCCGACCCCTGCC
 TTACCGGATACCTGTCGCCCTTCTCCCTGGAGCGTGGCGCTTCTCATAGCTCACGCTGT
 40 AGGTATCTCAGTTGGTGTAGGTCGTTGCTCCAGTGGCTTGGCTGGCTGTGACGAAACCCCGTTCA
 GCCCGACCGCTGCCCTTATCCGTAACTATCGTCTGGCTCAAGTCAGGGTGGCGAAACCCGACAGGACTT
 CGCCACTGGCAGCACCACTGGTAACAGGATTAGCAGAGGGAGTATCTAGGCGTGTACAGAG
 TTCTGAAAGTGGTGGCTAACTACCGCTACACTAGAAGGACAGTTGGTATCTGCGCTCTGCT
 GAAGCCAGTTACCTCGGAAAAGAGTTGGTAGCTTGTATCCGCAACAAACACCGCTGGTA
 45 GCGGTGGTTTTTGTGCAAGCAGCAGATTACCGCGAGAAAAAGGATCTCAAGAAGATCCT
 TTGATTTTCTACGGGCTGACGCTCACTGGAAACGAAACTCACGTTAAGGGATTGGTCA
 GAGATTATAAAAGGATCTTCACCTAGATCCTTTAAATTAAAATGAAGTTAAATCAATCT
 AAAGTATATAATGAGTAAACTTGGTGTACAGTTACCAATGCTTAATCACTGAGGACACCTATCTCA
 GCGATCTGCTATTGCTCATCCATAGTGGCTGACTCCCGCTGTAGATAACTACGATACG
 50 GGAGGGCTTACCATCTGGCCCACTGCTGCAATGATACCCGAGACCCACGCTCACCAGCTCCAG
 ATTATCAGCAATAAAACCGCCAGGCCAGGGAGGGCGAGCCAGAAGTGGCTGCAACTTATCC
 GCCTCCATCCAGCTTATTAATTGTTGCCGGAAAGCTAGAGTAAGTAGTGGCTGCAATTAGTT
 GCGCAACGTTGGTGCCTGAGGCTACGTTGCTGACGCTCGTGTGTTGGTATGGCTTCA
 TCAGCTCCGTTCCCAACGATCAAGCGACTTACATGATCCCCATGTTGCAAAAAGCGGTT
 55 AGCTCCTCGGTCTCCGATCGTTGCAAGAGTAAGTTGGCCGAGCTGTTATCACTCATGGTT
 GGCAGCACTGCATAATTCTCTACTGTGATGCCATCCGTAAGGATGCTTTCTGTAAGTGGT
 ACTCAACCAAGTCATTCTGAGAATAGTGTATGCCGCCGACCGAGTTGCTTGGCCGCTCAACA
 CGGGATAATACCGGCCACATAGCAGAACTTTAAAGTGTCACTATTGAAAAGCTTCTCGGG

GCAGAAACTCTAAGGATCTTACCGCTGTTGAGATCCAGTCGATGTAACCCACTCGTCACCCA
 ACTGATCTTCAGCATCTTACTTCACCAAGCTTCTGGGTGAGCAAAAACAGGAAGGCAAAT
 GCCGCAAAAAGGGAAATAAGGGCAGACGGAAATGTTGAATACTCATACTCTTCCTTTCAATC

5

DNA sequence pPO111-R3 5519 b.p. complete sequence;

CAGATCTGAGCTTGCATTGCATACGTTGATCCATATCATAATATGACATTATGGCTCA
 TGTCCAACATTACGCCATGTTGACATTGATTATTGACTAGTTATTAAATAGTAATCAATTACGGG
 10 GTCATTAGTTCATAGCCCATATATGGACTTCCGGCTTACATAACTTACGGTAATGGCCCGCTG
 GCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA
 ATAGGGACTTCCATTGACGTCAATGGGTGGAGTATTACGGTAACCTGCCACTTGGCAGTACA
 TCAAGTGTATCATATGCCAAGTAGCAGCCCCATTGACGTCAATGACGTAAATGGCCCGCTG
 ATTATGCCAGTACATGACCTTGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATC
 15 GCTATTACCATGGTATGCGGTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTCACG
 GGGATTTCAGTCTCCACCCATTGACGTCAATGGGAGTTGTTGGCACCAAAATCAACGGG
 ACTTTCCAAATGTGTAACAACCTCCGCCATTGACGCAAATGGGCGTAGGGTGTACGGTGG
 GAGGTCTATATAAGCAGAGCTCGGGGTCGGGCTGCACATTGTTGACGTGCGGCC
 AGATTGCAATCTGAATAAAACTTTTTCTGAATCCTCAGATTGGCAGTGAGAGGAGATT
 20 TGTTCGTGGTGTGCGCTGGCTACTGGTGGCGCAGGGATCCGACTGAATCCGTAGTACTTCG
 GTACAACATTGGGGCTCGTCCGGGATACCCCTCCATCGCAGAGGTGCCAACCTGCTTCTCG
 AACTTTCTCGAACCTCCGCCGGTGAAGTTAAGTACTTGTATTGGTACCTCCGAGGGTTGG
 GAGGATCGGAGTGGTGGCGGGACGCTGCCGGAAAGCTCCACCTCCGCTCAGCAGGGGACGCC
 ACCTGAGCTGAACTCAGATCTGTGTTATCTGATTGTTGAGCCGTCCTAACAGGGTATA
 25 CTAAGTCGTGGCTTGTGTGTTGTTGCGCTTGTGTTGTTGCGTGTGTTGACAGCGCCTT
 GCGAATTGGTGTACCCACACCCCGCGCTTGCATAACTTGGAGAGCCTTGCCTCCAGT
 GTCTCCGTCTGACTCGTCCCTCTCCCTCCGGGGAGAGCTCGCCGGGGATCCTCTA
 GTATGGTGCACTCTCACTACAACTCTGCTCTGATGCCCATAGTTAAGCAGTATAACCTCC
 TCGCTACGTGACTGGTATGCCGTCGCCCGACACCCGCAAACACCGCTGACGCCCTGACG
 30 GCCTTGTCTGCCGGCATCGCTTACAGACAAGCTGTGACCGCTCCGGAGCTGATGTC
 AGAGGTTTACCGTATCACCGAAACCGCGAGGCAGCTGGAATGTTGTCAGTTAGGGTGT
 GAAAAGTCCCCAGGCTCCCGAGGCAAGATGCAAAGCATCTCAATTAGTCAGCAAC
 CAGGCTCCCGAGGCAAGATGCAAAGCATCTCAATTAGTCAGCAACCATAGTCC
 CCCCTAACCTCCGCCATCCCCCTAACCTCCGGCAGTCCGGCCATTCTCCGGCCATGGCT
 35 ACTAATTTTTTATTATGCAAGGGCGAGGCCGCTCGGCTCTGAGCTATTCCAGAAGTAGT
 GAGGAGGCTTTTGAGGCTAGGCTTTGCAAAAGCTCTAGGTGACCTGCAAGCTCGCC
 GATCCCCGGGGCAATGAGATATGAAAAGCCTGAACTCACCGCAGCTGTCAGAAGTTCT
 GATGAAAAGTTCGACAGCTCCACCTGATGAGCTCCGGAGGGCAAGAATCTCGTCT
 TCAGCTCGATGTTAGAGGGCTGGATATGCTCTGCGGGTAAATAGCTGCCGCGATGGTTCTAC
 40 AAAGATCGTTATGTTATGCCACTTGTGATCGGCGCTCCGATTCCGAAGTGCTTGACAT
 TGGGAATTACCGGAGAGCCTGACCTATTGATCTCCCGCTGACAGGGTGTCACTGCAAG
 ACCTCCTGAAACCGAAGCTCCCGCTGTTCTGACGCCGTGCCGGAGGCATGGATGCC
 GCGGCGATCTTAGCCAGACGAGCGGGTCCGGGCAAGGAAATCGGTCAATACAC
 TACATGGCGTATTATGCCGATTGCTGATCCCCATGTTATCACTGGCAAACGTGATGG
 45 ACGACACCGTCAGTGGCTCCGCGCAGGCTCGATGAGCTGATGCTTGGGCCAGGACTGC
 CCCAAGTCCGGCACCTCGACGCCGATTCCGGCTCCAAACATGCTGACGGACAATGGCG
 CATAACAGCGTCATTGACTGGAGCGAGGCATGTTGGGGATTCCCAATACAGGTGCC
 TCTCTTCTGGAGGCCGTGGTGGCTGTATGGAGCAGCAGACGCCACTTCCAGCGGAGGC
 CCCGAGCTGCAAGGATGCCCGGGCTCCGGCGTATATGCTCCGATTGGTCTGACCAACTCTA
 50 TCAGAGCTGGTGAAGGCAATTGATGATGAGCTGGGCCAGGGTGTGACGCCAATCG
 TCCGATCCGGAGGGGACTGTCCGGCGTACACAAATGCCCGAGAGCGCGCCGCTGGACC
 GATGGCTGTGAGAAGTACTCGCCGATAGTGGAAACCGACGCCAGACTGTTGGGATCAGCTT
 GGCACGGAAATTAAATTCTCATGTTGACAGCTTATCGATAAGCTCTAGGTCAATGGTTGAC
 CAGAACATACAGAGCAGTGGGAATGTTGGAGGGCCTCGAGGTGCGGGTGCCTACACAT
 55 TGTGTTGTGACGTGCGGCCAGATTGAACTGTAATAAAACCTTTTAACTGAATCCTCAG
 ATTGGCAGTGAAGGGAGTTGTTGTTGAGCTGGCTGGCTACTGGGTGGCGCAGGGATCGA
 TCCAGACATGATAAGTACATTGATGAGTTGGACAAACCAACTAGAAATGCAAGTAAAAAAT
 GCTTTTTGTGAAATTGATGCTATTGCTTATTGTAACCAATTATAAGCTGCAATAACAA

GTTAACAACAACAATTGATTCACTTATGTTCAGGTTAGGGGGAGGTGAGGTTTTA
 AAGCAAGTAAACCTCTACAAATCAAGCTGATCCCTGCCTCGCGCTTCGGTATGACGGTGA
 AACCTCTGACACATGCAGCTCCCGAGACGGTCACAGCTTGTGTAAGCGGATGCCGGAGCAG
 ACAAGCCCGTCAAGGGCGCTCAGGGGTGTTGGGGGTGTCGGGGCGAGCCATGACCCAGTCAC
 5 GTAGCGATAGCGGAGTGATACTGGCTTAACATGCGGCATCAAGAGCAGATTGACTGAGAGTGC
 ACCATATGCGGTGTAATAACCGCACAGATCGCTAAGGAGAAAATACCGCATCAGGCCTCTTC
 GCTTCCTCGCTCACTGACTCGCTCGCTCGGCTCGGCGAGCGGTATCAGCTCACTC
 AAAGCGGTAATACGGTTATCCACAGAATCAGGGATAACCGAGGAAAACATGTGAGCAAAG
 GCCAGCAAAGGCCAGGAACCGTAAAGGCCCGTTGCTGGGTTTTCATAGGCTCCGCCCC
 10 CCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGGAAACCCGACAGGACTATAAAG
 ATACCAAGCGTTCCCTGGAAAGCTCCCTCGTCGCTCTCCTGTTCCGACCCCTGCCGTTACCG
 GATACTCTCCGCTTCTCCCTCGGGAAAGCGTGGCGTTCTCATAGCTCACGCTGTAGGTAT
 CTCAGTTGGTGTAGGTGTTCCCTCAAGCTGGCTGTGACGAAACCCCGTTAGCCGA
 CCCCTGCCCTTACCGTAACATCGCTTGAAGTCAACCCGTAAGACACGACTATCGCAC
 15 TGGCAGCAGCCACTGGTAACAGGATTAGCAGACGGAGGTATGAGGCGGTGCTACAGAGTTCTG
 AAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGTAAGCC
 AGTTACCTTCGGAAAAAGAGTTGGTAGCTTGTGATCCGGCAAACAAACCCCGTTAGCGGTG
 GTTTTTGTTGCAAGCAGCAGATTACCGCAGAAAAAAAGATCTCAAGAAAGATCTTGTAC
 TTTCTACGGGCTGACGCTCAGTGGAACGAAAACACGGTTAACGGGTTTTGGTATGAGATT
 20 ATCAAAAAGGATCTCACCTAGATCCTTAAATTAAAATGAAGTTAAATCAATCTAAAGTA
 TATATGAGTAACCTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGACCTATCTAGCGATC
 TGCTATTCGCTCATCCATAGTGGCTGACTCCCCCTGCTGAGATAACTACGATACGGGAGGG
 CTTACCATCTGGCCCAGTGTGCAATGATACCGCAGACCCCGCTCACCGGCTCCAGATTAT
 CAGCAATAAAACCGCCAGCGGAGGGCCAGACGGCAGAAGTGGTCTGCAACTTATCCGCTCC
 25 ATCCAGTCTATTAATTGTGCGGGAAAGCTAGAGTAAGTAGTGTGCGCAGTTAATAGTTGCGCAA
 CGTTGTTGCCATTGCTGCAAGGCATCGTGGTCAAGCGCTGTCGTTGGTATGGCTTCAATTGAGT
 CCGGTTCCCAACGATCAAGGGAGTTACATGATCCCCATGTTGCAAAAAGCGGTTAGCTCC
 TTGGTCTCCGATCGTGTGAGAAGTAAGTTGGCCGAGTGTGTTACTCATGGTTATGGCAGC
 ACTGCATAATTCTTACTGTATGCCATCCGTAAGATGCTTCTGACTGGTAGTACTCAA
 30 CCAAGTCATTCTGAGAATAGTGTATGGGGCAGCTGGTCTGCGCCGGCTCAACACGGGAT
 AATACCGGCCACATGCGAGACTTTAAAGTGTCTCATATTGGAAACGTTCTCGGGGCAA
 ACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTGATGTAACCCACTCGTCACCCAAGTGT
 CTTCAGCATCTTACTTCACTTACCCAGCGTTCTGGGTGAGCAGGAAACAGGAAGGAAATGCCGA
 AAAAGGAAATAAGGGCGACCGAAATGTTGAATACTCATCTCCCTTTCAATC
 35

DNA sequence PPO115-R1 3878 b.p. complete sequence;

CAGATCTGAGCTGCCATTGATACGTTGATCCATATCATAATATGACATTATGGCTCA
 40 TGTCACACATTACCGCATGTTGACATTGATTGACTAGTTAAATAGTAATCAATTACGGG
 GTCATTAGTCATAGCCATATGGAGTCCCGTACATAACTACGGTAATGGCCGCTG
 GCTGACCGCCCAACGACCCCCCGCCATTGACGTCATAATGACGTATGTCCTCATGTAACGCCA
 ATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTAACGTTAACTGCCACTTGGCAGTACA
 TCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGTAAATGGCCGCTGGC
 45 ATTATGCCAGTACATGACCTATGGGACTTCTACTTGGCAGTACATCTACGTTAGTCATC
 GCTATTACCATGGTGTGCGGTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTGACTCACG
 GGGATTCCAACTCTCCACCCATTGACGTCATGGGAGTTGGCACCACAAATCACGGG
 ACTTTCAAATGTGTAACAACCTCCGCCCCATTGACGCAAATGGGAGTAGGGTGTACGGTGG
 GAGGTCTATATAAGCAGAGCTCATCTTGTGCGGGTGCCTGCACATTGGTGTGAC
 50 GTGCGGCCAGATTGAACTGTAAATAAAACTTTTTCTGTAATCCTCAGATTGGCAGTGAG
 AGGAGATTTGTTCTGTTGGTGTGCTGGCTACTGGGGGGCGAGGGATCCGACTGAATCCGT
 AGTACTTCGGTACAACATTGGGGCTCGTCCGGGATACCCCTCCCATGGCAGAGGTGCAACT
 GCTTCTCGAACTTCTCGAACTCCGGCGCCGGTGAAGTTAACTTGATTTGGTACCTCGG
 AGGGTTGGGAGGATCGGAGTGGGGGGAGCCTGCGGGAAAGCTCCACCTCCGCTCAGCAGGG
 55 GACGCCCTGACCTGAGCTGTGTTATCTGATTGTTGTTGAGCCGTCCTAAGACGGTGTACTA
 AGTCGTGGCTTGTGTTGTTGCTTGTGTTGTCGTCGTTGTCGACAGCGCCTTGG
 AATTGGTGTACCCACCCGCGCGCTTGCATAATACTTTGGAGAGGCCCTTGCCTCAGTGT
 TTCCGCTGTACTCGTCTCTCCCTCCGGCGCTCTAGAACTAGTGGATCCCCGGGCTG

CAGGAATTCGATATCAAGCTTATCGATAAGCTCTAGGTCAATGGTTGACCAGAACATAAAGAG
 CAGTGGGAATGTGGGAGGCCTCGAGGTGGGTCGCCCTACACATTGTTGTGACGTG
 CGGCCAGATTCGAATCTGATAAAAACCTTTAACTGAATCCTCAGATTGGCAGTGAGAGG
 AGATTTGTCTGGTGTGGCTGGCTACTGGTGGGCGCAGGGATGATCCAGACATGATAAG
 5 ATACATTGATGAGTTGGACAACACAACTAGAATGCACTGGTAAAGGAACTGTTATTTGAAAG
 TTTGTATGCTATTGTTATTGTAACCATTAAAGCTGCAATAAAACAAGTTAACAAACAACT
 TGCAATTCAAGCTGATCCCTGCCTCGCGCGTTCGGTATGACGGTGAAACCTCTGACACATG
 CAGCTCCGGAGACGGTACAGCTGTGTAAGCGGATGCCGGAGCAGACAAGCCGTCAAGGG
 10 CGCGTCAGCGGTGTTGGGGTCTGGGGCGACCCATGACCCAGTCACGTAGCGTAGCGGAG
 TGATACTGGCTTAACATGCGGCATCAGAGCAGATTGACTGAGAGTGACCATATGCGGTGTG
 AAATACCGCACAGATGCGTAAGGGAAAAATACCGCATCAGCGCTTCCGCTCCTCGCTCACT
 GACTCGCTCGCTCGGTGCTCGCTGCGCGAGCGGTATCAGCTCACTCAAAGCGGTAATACG
 GTTATCCACAGAATCAGGGATAACGCAAGAAAGAACATGTGACCAAAGGCCAGCAAAGGCCA
 15 GGAACCGTAAAAAGGCCGTTGCTGGCTTTCCATAGGCTCGCCCCCTGACGAGCATCAC
 AAAATCGACGCTCAAGTCAGAGGTGGCAGACCGACAGGACTATAAGATAACCGGTTTCC
 CCCTGGAAGCTCCCTCGTCGCTCTCCGTTCCGACCCCTGCCGTTACCGGATACTGTCGGCCT
 TTCTCCCTCGGGAAAGCTGGCTTCTCATAGCTCACGCTGAGGTATCTCAGTTGGTAG
 GTCGTTCGCTCAAGCTGGCTGTGCAACGAAACCCCGTCAAGCCCACCGCTGCGCTTATC
 20 CGGTAACATCTGCTTGGATCAACCCGGTAAGACACGACTATTCGCACTGGCAGCAGCCACTG
 GTAACAGGATTAGCAGAGCAGGTATGAGGGCTACAGAGTTCTGAAGTGGTGGCCTAAC
 TACCGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTACCTTGGAAA
 AAGAGTTGGTAGCTTGTGATCCGGAAACAAACCCACCGCTGGTAGCGGTGGTTTTTTGTTGCA
 AGCAGCAGATTACGGCAGAAAAAAAGGATCTAAGAAGATCTTGTATCTTCTACGGGCT
 25 GACGCTCAGTGGAAACAAAACACGGTAAAGGGATTTGGTCATGAGATTATCAAAGGATCTT
 CACCTAGATCTTAAATTAAAATGAGTTAAATCAATCAAAGTATATGAGTAACCTT
 GGTGACAGTACCAATGCTTAACTCACTGAGGCACCTATCTCAGCGATCTGCTATTGTTCA
 TCCATAGTTGCTGACTCCCCCTGCTGAGATAACTACGATACGGGAGGGCTTACCATCTGGCC
 CAGTGCCTGAATGATAACGGCAGACCCACGCTACCGGCTCAGATTACGCAATAACCAAGC
 30 CAGCGGAAGGGCCGACCGCAAGTGCTCTGCAACTTTATCCGCTCCATCCAGTCTATTAAAT
 TGTTGCCGGAAAGCTAGAGTAAGTGTGCTGCCAGTTAATAGTTTGCGCAACGTTGCTGCT
 TGCAAGGCATCGTGTGCTACGCTCGTGTGGTATGGCTTACCTCAGCTCCGGTCCCGAT
 CAAGGGCAGTTACATGATCCCCATGTTGTGCAAAAGCGGTAGCTCTGGTCTCCGATC
 GTTGTCAAGAGTAAAGTGGCCCAAGTGTACTCATGTTATGGCAGCACTGCATAATTCTCT
 35 TACTGTCATGCCATCCGTAAGATGCTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTGAG
 AATAGTGATGGGGCAGCCGAGTTGCTCTGGCCGGCTCAACACGGATAATACCGCGCACAT
 AGCAGAACTTTAAAGTGTCTCATGGAAACGTTCTTCCGGGCGAAACTCTAAGGATCTT
 ACCGCTGGTGAAGATCCAGTTCGATGAAACCCACTGTCACCCACTGATCTCAGCATCTTTA
 CTTCACCAAGCTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCCAAAAAGGGATAAGG
 40 GCGACACGGAAATGTGAATACTCATACTCTCCTTTCAAT

Throughout this application, various publications have been
 referenced. The disclosures in these publications are incorporated herein by
 45 reference in order to more fully describe the state of the art.

Appendium of References

- Anderson,W.F., Wagner,E.F., and Gilboa,E. 1986. Self-
 50 inactivating retroviral vectors designed for transfer of whole genes into mammalian
 cells. Proc. Natl. Acad. Sci. USA 83:3194-3198.

- Boshart,M., Weber,F., Jahn,G., Dorsch-Haesler,K., Fleckenstein,B., and Schaffner,W. 1985. A very strong promoter is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521-530.
- 5 Dornburg,R. and Temin,H.M. 1988. Retroviral vector system for the study of cDNA gene formation. Mol. Cell. Biol. 8:2328-2334.
- Dougherty,J.P. and H.M. Temin. 1987. A promoter-less retroviral vector indicates that there are sequences in U3 required for 3'RNA processing.
- 10 Proc. Natl. Acad. Sci. USA 84, 1197-1201.
- Dougherty,J.P. and Temin,H.M. 1989. New retrovirus helper cells with almost no nucleotide sequence homology to retrovirus vectors. J.Viro. 63,3209-3212.
- 15 Embretson,J.E., and H.M.Temin. 1987. Lack of competition results in efficient packaging of heterologous murine retroviral RNAs and reticuloendotheliosis encapsidation-minus RNAs by the reticulo-endotheliosis virus helper cell line. J.Viro. 61,2675-2683.
- 20 Kewalramani,V.,N., Panganiban,A., and Emerman,M. 1992. Spleen necrosis virus, an avian immunosuppressive retrovirus, shares a receptor with the type D simian retroviruses. J. Viro. 66:3026-3031.
- 25 Markowitz,D., Goff,S., and Bank,A. 1988. A safe packaging line for gene transfer: separation of viral genes on two different plasmids. J. Viro. 62:1120-1124.
- P. Olson, H.M.Temin, and R.Dornburg. (1992) Unusually high frequency of reconstitution of LTRs in U3 minus retrovirus vectors by DNA recombination or gene conversion. J. Viro. 66:1336-1343
- 30 35 W.Sheay, I.Martinez, T.-H.T. Chu, S.Nelson, S.Bhatia, and Ralph Dornburg (1992) The adenovirus leader sequence enhances gene exression when inserted downstream of various promoters in universal gene expression vectors (submitted to "Biotechniques").

Temin,H.M. 1986. Retrovirus vectors for gene transfer: efficient integration into and expression of exogenous DNA in vertebrate cell genomes, in "Gene Transfer" (R.Kucherlapati,ed.) Plenum Press, New York.

5 Watanabe,S., and H.M.Temin. 1983. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol. Cell. Biol. 3, 2241-2249.

10 Yu,S.-F., Rueden,T., Kantoff,P.W., Garber,C., Seiberg,M., Ruether,U., Anderson,W.F., Wagner,E.F., and Gilboa,E. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. 83:3194-3198.

15 The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

I claim:

- 5 1. A recombinant retrovirus vector having a U3-free 5' LTR, a partially deleted 3' LTR, all essential cis-acting sequences for replication, an internal promoter recognizable by a selected host cell, and a non-retroviral gene under the control of the recognized promoter wherein:
 - (a) the U3-free 5' LTR is positioned 5' of the non-retroviral gene and has a transcriptional promoter and enhancer different from that of the original retroviral promoter and enhancer replacing the original U3 region of the 5'LTR;
 - 10 (b) the partially deleted 3' LTR is positioned 3' of the non-retroviral gene and has no U3 sequences except for those required at the attachment site for viral integration;
 - 15 (c) an exogenous polyadenylation addition signal sequence recognized by the selected host cell and positioned on the vector 3' to the 3' LTR viral integration site; and
 - 20 (d) the internal recognized promoter is positioned adjacent to the non-retroviral gene on the vector to permit expression of the non-retroviral gene in the host cell;
 whereby the vector can produce progeny virus in a helper cell with the progeny virus being capable of infecting the selected host cell and forming a provirus in the host cell, with the non-retroviral gene being expressible in the host cell, but the provirus in the host cell will be replication incompetent even in the presence of a helper virus.
- 25 2. A retrovirus produced by the recombinant retrovirus vector of claim 1.
3. A host cell containing the provirus of claim 1.

FIGURE 1




A**B**

FIGURE 2

A

RETROVIRAL VECTOR PROVIRUS



B






FIGURE 3

FIGURE 4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/06415

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C12N 7/00, 7/01, 15/00, 15/48, 15/85

US CL :435/69.1, 91.1, 91.4, 172.1, 240.2, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 91.1, 91.4, 172.1, 240.2, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Biosis, Biotech, Medicine, Medline

Search terms: retrovirus, U3, Long terminal repeat, viral vector

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,124,263 (TEMIN ET AL.) 23 June 1992, see whole document.	1-3
Y	Journal of Virology, Volume 66, Number 3, issued March 1992, Olson et al., "Unusually High Frequency of Reconstitution of Long Terminal Repeats in U3-Minus Retrovirus Vectors by DNA Recombination or Gene Conversion", pages 1336-1343, see Figures 1 and 2.	1-3

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
21 JULY 1994	AUG 02 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 308-3230

Authorized officer
DAVID GUZO
Telephone No. (703) 308-0196